Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a strong sell rating in a report released on Thursday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Piper Sandler raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $40.00 to $65.00 in a report on Thursday, October 9th. TD Cowen increased their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Stifel Nicolaus upped their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $48.16 on Thursday. The firm has a market cap of $2.76 billion, a price-to-earnings ratio of -141.64, a price-to-earnings-growth ratio of 0.52 and a beta of 0.67. The business has a 50-day simple moving average of $48.76 and a two-hundred day simple moving average of $46.18. Supernus Pharmaceuticals has a fifty-two week low of $29.16 and a fifty-two week high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The company had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $175.82 million. During the same quarter in the prior year, the firm posted $0.69 earnings per share. Supernus Pharmaceuticals’s quarterly revenue was up 9.3% on a year-over-year basis. As a group, research analysts predict that Supernus Pharmaceuticals will post 2.38 earnings per share for the current year.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares of the company’s stock, valued at $781,153.36. The trade was a 56.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the completion of the sale, the vice president owned 14,508 shares of the company’s stock, valued at $644,735.52. The trade was a 4.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in SUPN. Royal Bank of Canada lifted its position in Supernus Pharmaceuticals by 68.1% during the first quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock valued at $382,000 after acquiring an additional 4,729 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 35.2% during the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock worth $2,791,000 after purchasing an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Supernus Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after purchasing an additional 1,297 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Supernus Pharmaceuticals by 370.5% during the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after purchasing an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC boosted its position in shares of Supernus Pharmaceuticals by 16.0% in the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after purchasing an additional 6,619 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.